PPD

OCTOBER 31, 2024

In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drug developers to capture a comprehensive view of these evolving trends. This aims to ensure that treatments are effective across varied demographics and to address historical gaps in clinical research.

Drug Development

Drug Patent Watch

DECEMBER 11, 2024

It is crucial to determine whether you will be working with a CDMO for discovery and drug development all the way through approvals and commercialization or if your work with a CDMO will begin with preclinical development or clinical research. 2024, March 13). References Ajinomoto Bio-Pharma Services. 2019, March 6). Contract Pharma.

Pharmaceutical Companies

Drug Target Review

JUNE 16, 2025

1 Continuous advancements in sensitivity and spatial resolution support the role of MSI in pharmaceutical research. By integrating MSI with histopathology, clinical chemistry and DMPK data, researchers can develop mechanistic hypotheses of toxicity, improving decision making and reducing unnecessary follow-up studies. References [1].

Drugs

Broad Institute

NOVEMBER 4, 2024

By Lucy Mutz November 4, 2024 Credit: Juliana Sohn Kasper Lage is managing director of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease. To this day, I don't know who said it first, but we noted that the NNF had been sponsoring thematic research centers in Denmark for over a decade.

Disease

Drug Target Review

JUNE 11, 2025

Multimodality however can detect and connect trends (and in future generate content) across different modalities and therefore allows for better interpretability, which builds trust between regulators, researchers and industry stakeholders. 2024 Dec 26; Available from: [link] Geukes Foppen RJ, Gioia V, Velez CN. Lifescienceleader.com.

Drugs

Drug Target Review

JUNE 30, 2025

After nearly two decades at GSK, where he served as Head of Research, he left to take a bold leap into the unknown: the expanded human proteome. He joined ProFound following 17 years at GSK, where he most recently served as Senior Vice President and Head of Research. And the big players are taking notice.

Disease

Broad Institute

OCTOBER 29, 2024

New drug triggers rapid cell death in cancer models By Karen Zusi-Tran October 29, 2024 Breadcrumb Home New drug triggers rapid cell death in cancer models BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models. Online August 23, 2024. Paper cited Rauh U, et al.

Drugs

Covalent Modifiers

NOVEMBER 18, 2024

Conghao Gai, Hairong Zeng , Haoming Xu, Xiaoyun Chai, Yan Zou, Chunlin Zhuang, Guangbo Ge, Qingjie Zhao European Journal of Medicinal Chemistry, 2024 [link] Isocitrate dehydrogenase (IDH) is an enzyme that catalyses the oxidative decarboxylation of isocitrate, producing α-ketoglutarate (α-KG) relative to the hydroxylation of substrates.

Drugs

Broad Institute

APRIL 5, 2025

During his doctoral research at University of California Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He is the 2022 King Faisal Prize Laureate in Medicine, and the recipient of the 2024 Gabbay Award in Biotechnology and Medicine.

Science

New Drug Approvals

APRIL 25, 2025

3] Inavolisib was approved for medical use in the United States in October 2024. [3] 3] Inavolisib was approved for medical use in the United States in October 2024. [3] 11 October 2024. Retrieved 11 November 2024. 10 October 2024. Retrieved 11 October 2024. 1 October 2024. 3 November 2006.

FDA

Drug Target Review

JUNE 9, 2025

AP003: a promising candidate for rare liver diseases In December 2024, Alltrna announced its first development candidate, AP003, an engineered tRNA formulated in a lipid nanoparticle.

Disease

PPD

NOVEMBER 11, 2024

According to the United Nation’s 2024 World Population Prospects data, the global population of those 65 years old and over will grow from 0.8 From an aging population increasing health care demand to urgent, unmet medical needs, there are clear drivers to advance safe and effective medicines to patients faster than ever. billion in 2035.

Drug Development

The Pharma Data

JUNE 23, 2025

Executive Vice President of Research and Development at Amgen, emphasized the broader implications of these findings. professor at Yale School of Medicine and director of the Y-Weight Yale Obesity Research Center. Expert Perspective: A Potential Paradigm Shift in Obesity Treatment Dr. Jay Bradner, M.D.,

Trials

Drug Target Review

JUNE 19, 2025

As the limitations of current treatments become increasingly clear, researchers are exploring new, safer approaches. As co-founder and chief executive of South Rampart Pharma , and a practicing academic vascular surgeon, Dr Bazan combines hands-on clinical experience with a strong track record in scientific research.

Clinical Trials

Alta Sciences

JUNE 6, 2025

For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. About the Author Martin Rougée joined Altasciences in early 2024 as an Optimization Scientist. Tags Bioanalysis Preclinical Research Weight 15

Pharmacokinetics

Fierce BioTech

NOVEMBER 22, 2024

AI in Pharma: Benefits, Risks and the Road Ahead AI is revolutionizing the drug development process, streamlining and accelerating every stage, from research to approval and marketing. This whitepaper explores the benefits and risks of AI in the pharmaceutical industry and examines its future.

Drug Development

Drug Target Review

DECEMBER 9, 2024

The 2024 Nobel Prize in Chemistry was awarded to Demis Hassabis and John Jumper from Google DeepMind for developing AlphaFold2, and to David Baker from the University of Washington for his work in computational protein design. These innovations have revolutionised the understanding of protein structures using artificial intelligence.

Engineering

Drug Target Review

NOVEMBER 11, 2024

To overcome these escape mechanisms researchers are exploring a wider arsenal of therapeutic strategies. This has been highlighted in poster presentations at the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). 2024: 25(7):853-864. 2024: 84(6). The Lancet Oncology.

Immune Response

Broad Institute

NOVEMBER 25, 2024

Ladders to Cures (L2C) Accelerator By Maria Nemchuk November 25, 2024 Breadcrumb Home Ladders to Cures (L2C) Accelerator The Ladders to Cures (L2C) Accelerator aims to catalyze progress across the research ecosystem and accelerates advances leading to treatments and cures for patients with rare genetic diseases. Visit broad.io/L2C2023

Clinical Trials

The Pharma Data

JUNE 20, 2025

As of the data cutoff in October 2024, each of these participants had completed at least 12 months of follow-up. Medical Director of the Pancreatic Islet Cell Transplant Program at the University of Pennsylvania and a leading authority in diabetes research. The presentation at the ADA meeting was delivered by Dr. Michael R.

Therapies

PPD

DECEMBER 16, 2024

The drug development industry faces rising costs and increasingly complex protocols as top challenges, with 49% of developers citing costs as their primary concern and 39% pointing to protocol complexity as a key hurdle, according to a recent survey of 150 drug developers worldwide by the PPD clinical research business of Thermo Fisher Scientific.

Drug Development

Alta Sciences

DECEMBER 31, 2024

One of the most important factors to consider during the course of your early-phase clinical research is drug-drug interactions (DDIs), which occurs when one drug alters the effect of another, either by reducing its effectiveness or elevating systemic concentrations to potentially dangerous levelsultimately causing side effects.

Therapies

Alta Sciences

FEBRUARY 19, 2025

Researchers must characterize the anti-drug-antibody (ADA) response in preclinical and clinical studies and report any ADA-positive samples as a risk-based approach. Regulatory Considerations for Oligonucleotide Drug Development and Safety In 2024, the U.S.

Drug Development

Drug Target Review

APRIL 7, 2025

2 Considering 2530 percent of marketed drugs work by binding to GPCRs, 3 it is vital that these challenges are overcome through innovation and research. This crucial role in regulating vital bodily processes makes it a highly important drug target within GPCR research. Available at: [link] (Accessed: 23 September 2024).

Fragment Screening

Drug Target Review

MAY 21, 2025

These materials are vital for researchers working on drug candidate identification, early-phase biologic testing, and mechanism-of-action studies, ultimately accelerating the drug discovery pipeline. Prior to joining Vitalant, Cap held executive, research and consulting roles in the life sciences industry.

Therapies

Alta Sciences

MARCH 4, 2025

Addressing New Challenges in Human Abuse Potential Research The CCALC has held face-to-face meetings in collaboration with industry, academia, and the FDA once every two to three years since inception, and has provided much of the industry perspective on the practical challenges and solutions to assessing abuse and dependence potential.

Clinical Trials

Codon

APRIL 17, 2025

In 2016, researchers František Baluška and Stefano Mancuso suggested that ocelli could also explain Boquila ’s uncanny shape-shifting ability, positing that these “tiny eyes” may actually be capable of sight. Here is a time-lapse video of a plant moving in response to changing sunlight.)

Research

The Pharma Data

JUNE 22, 2025

Part one of the GMMG-HD7 study was presented at the 2024 American Society of Hematology (ASH) Annual Meeting and simultaneously published in the Journal of Clinical Oncology.

Therapies

The Pharma Data

JUNE 15, 2025

Safety Profile and Tolerance Across all the investigated dose cohorts, lonvo-z was well tolerated and demonstrated a favorable safety profile, consistent with previously presented data at the 2024 EAACI meeting.

Treatment

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D

The Pharma Data

JULY 2, 2025

Importantly, nearly all participants in the Phase 1b trial had previously enrolled in an observational natural history study initiated by argenx in 2024. Peter Ulrichts, Ph.D., argenx remains focused on uncovering new biological insights into misunderstood diseases to meaningfully change the lives of patients who have long-been underserved.”

Clinical Trials

Alta Sciences

NOVEMBER 15, 2024

4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey. Image thumbnail_Blog_Chad and Lisa_v3.jpg Tags About Altasciences Weight 16

Drug Development

Alta Sciences

NOVEMBER 13, 2024

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services.

Clinical Pharmacology

Common Sense for Drug Policy Blog

NOVEMBER 26, 2024

"Pink Cocaine", Otherwise Known As Tusi "The tusi phenomenon complicates the drug landscape because it has the potential to confuse both people who use and researchers alike. The tusi phenomenon also has the potential to complicate drug research. dwf_admin Tue, 11/26/2024 - 11:50 Source Palamar JJ. Am J Drug Alcohol Abuse.

Production

New Drug Approvals

JULY 25, 2025

Syn EuropeanJournalofMedicinalChemistry265(2024)116124 Vamorolone (Agamree) On October 26, 2023, Vamorolone, developed jointly by Santhera Pharmaceuticals and ReveraGen BioPharma, has received FDA approval to treat DMD in patients aged 2 years and older [1]. Drugs 2024, 84, 111− 117. (71) 16 February 2024. 70) Keam, S.

FDA

The Pharma Data

JULY 2, 2025

I’m grateful that Biogen is prioritizing this rare disease and advancing research that could ultimately change clinical practice.” The rights to felzartamab were licensed to Human Immunology Biosciences (HI-Bio) , which Biogen acquired in July 2024.

Trials

New Drug Approvals

APRIL 2, 2025

acting director of the FDA’s Center for Drug Evaluation and Research. 00682] Compound 22 Solid Form A Efficacy When people used suzetrigine in clinical studies conducted through 2024, there was a reduction in pain typically from seven to four on the standard numerical scale used to rate pain. [7] 30 January 2024.

FDA